Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PGPratyush GiriTCTara CochraneMWMannu Walia

Discussion

Loading...

Member takes

Overview

Interim analysis of clinical trial shows high rates of complete response and ctDNA negativity in patients with PMBL, suggesting effective chemoimmunotherapy.

Key Points

  • 90% overall response rate was observed in the interim analysis of the ALLG-Pacific trial.
  • Forty-four percent of patients achieved complete response after initial cycles of Pembrolizumab and R-CHOP.
  • Patients who completed induction showed 100% overall response at the end of the window, indicating efficacy.
  • Pneumonitis and other immune-related toxicities were manageable, supporting the treatment's safety profile.

Cite This Study

Giri et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d41ahttps://doi.org/10.1182/blood-2025-1016
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China2025
  2. 2Final results from the embolden trial:  pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma2025
  3. 3Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025
  4. 4Pembrolizumab as an Unconventional First-line Salvage Therapy in Primary Mediastinal Large B-cell Lymphoma: A Case Report2025
  5. 5Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial2025 · 4 citations